Menu
The development of our product is rooted in scientific evidence that highlights the disruption in treating patients with unmet need and low efficiency in the target CNS disorders.
A mental disorder is characterized by a clinically significant disturbance in an individual’s cognition, emotional regulation, or behavior, as described by the International Classification of Diseases 11th Revision (ICD-11). It is usually associated with distress or impairment in important areas of functioning.
In 2019, 1 in every 8 people, or 970 million people around the world were living with a mental disorder.
While effective prevention and treatment options exist, most people with mental disorders do not have access to effective care, with 1 in every 9 individuals dying of a disorder of the nervous system, while many people also experience stigma, discrimination and violations of human rights.There are many different types of mental disorders. Mental disorders may also be referred to as mental health conditions. The latter is a broader term covering mental disorders, psychosocial disabilities and (other) mental states associated with significant distress, impairment in functioning, or risk of self-harm.
OCD affects approximately 1-3% of the global population (80-240 million people).
Epilepsy is a neurological disorder characterized by recurrent seizures. Globally, it’s estimated that around 50 million people have epilepsy.
The prevalence of Parkinson’s disease is estimated to be around 1-2% in people over 60 (80-160 million people), with approx. half of those suffering from Parkinson’s disease developing Parkinson’s disease dementia.
In the general population, the lifetime prevalence of PTSD is estimated to be around 7-8% (560-650 million people).
The estimated incidence, is around 7-10% of the global population (566-810 million people).
The global central nervous system therapeutics market size was estimated at US$ 98.56 billion in 2022 and is expected to reach over US$ 230.1 billion by 2032, growing at a CAGR of 8.90% from 2023 to 2032.
The rising prevalence of various central nervous system diseases among the population such as Alzheimer’s disease, Parkinson’s disease, brain cancer, anxiety disorders, and epilepsy is a major factor driving the markets continuous growth.
The disorders of the nervous system causing the highest rates of death and disability are preventable and treatable.
NEUROINNOVATECH’s target indications has a total projected sale of US$ 52 billion, of which PTSD and neuropathic pain is the largest contributors.
It is estimated that CNS disorders collectively represent a significant burden on global health. The prevalence varies depending on the specific disorder, however, the US is the largest market with approx. 45% of the market values.
